Article
Retail investors crowd into Eli Lilly after weight-loss drug approval
Rating:
0.0
Views:
52
Likes:
1
Library:
1
Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, when Zepbound was cleared in the U.S. and the U.K., hitting their highest levels since January 2021, as per data from Vanda Research.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value